Vanguard amendment shows 0 shares of 4D Molecular (NASDAQ: FDMT)
Rhea-AI Filing Summary
4D Molecular Therapeutics Inc Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that led certain Vanguard subsidiaries to report separately.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership after internal realignment.
The filing states Amount beneficially owned: 0 and Percent of class: 0%, indicating Vanguard does not claim beneficial ownership of 4D Molecular's common stock in this amendment. The disclosure cites SEC Release No. 34-39538 regarding disaggregation.
Cash-flow treatment and trading intentions are not stated; subsequent filings would show any holdings reaggregation or separate subsidiary reports.
Amendment documents compliance with SEC disaggregation guidance.
The text explains that Vanguard reorganized and that certain subsidiaries will report separately, consistent with SEC guidance. The filing includes the standard ownership table showing zeros for voting and dispositive powers.
This is an administrative/update filing; material impact depends on later separate reports by Vanguard entities.
FAQ
What does The Vanguard Group report for FDMT ownership?
Why did Vanguard file this Schedule 13G/A for FDMT?
Does this filing show any shares controlled by Vanguard subsidiaries for FDMT?
Who signed the FDMT Schedule 13G/A amendment for Vanguard?
Does the filing identify any party with more than 5% ownership of FDMT?